Search Results - "Garau, Isabel"

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade by Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix

“…The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, ∼20–60% of HER2+/HER2-E tumors…”
Get full text

Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study by Redondo, Andrés, Ramos Vázquez, Manuel, Manso, Luis, Gil Gil, Miguel J, Garau Llinas, Isabel, García-Garre, Elisa, Rodríguez, César A, Chacón, José Ignacio, López-Vivanco, Guillermo

“…Randomized controlled trials of the first-line combination of bevacizumab and chemotherapy in patients with metastatic breast cancer (MBC) have shown…”
Get full text

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial by Ciruelos, Eva, Villagrasa, Patricia, Pascual, Tomás, Oliveira, Mafalda, Pernas, Sonia, Paré, Laia, Escrivá-de-Romaní, Santiago, Manso, Luis, Adamo, Barbara, Martínez, Eduardo, Cortés, Javier, Vazquez, Silvia, Perelló, Antonia, Garau, Isabel, Melé, Mireia, Martínez, Noelia, Montaño, Alvaro, Bermejo, Begoña, Morales, Serafin, Echarri, María J, Vega, Estela, González-Farré, Blanca, Martínez, Débora, Galván, Patricia, Canes, Jordi, Nuciforo, Paolo, Gonzalez, Xavier, Prat, Aleix

“…To assess palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2-positive advanced breast cancer. PATRICIA is a…”
Get full text

Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer by Sastre-Serra, Jorge, Valle, Adamo, Company, Maria Margarita, Garau, Isabel, Oliver, Jordi, Roca, Pilar

“…Oxidative stress has been postulated as one of the mechanisms underlying the estrogen carcinogenic effect in breast cancer. Estrogens are known to increase…”
Get full text

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial by Colleoni, Marco, Luo, Weixiu, Hitre, Erika, Kamby, Claus, Müller, Bettina, Di Lauro, Vincenzo, Burstein, Harold, Bernhard, Jürg, Maibach, Rudolf, Rabaglio-Poretti, Manuela, Regan, Meredith M, Vandebroek, An, Berliere, Martine, Mitine, Carine, Vuylsteke, Peter, Glorieux, Philippe, Mebis, Jeroen, Coibion, Michael, Forget, Frederic, Duck, Lionel, Wyendaele, Wim, Pinotti, Graziella, Bernardo, Antonio, Biganzoli, Leo, Gennari, Alessandra, Forbes, John, Foo, Serene, Boyle, Frances, Abdi, Ehtesham, Na Teo, Lee, White, Shane, Gilbert, Linda, Dedes, Konstantin, Pagani, Olivia, Pedrazzini, Augusto, Rochlitz, Christoph, von Moos, Roger, Fehr, Mathias, Nyman, Per, Foukakis, Theodoros, Dabrosin, Charlotta, Fritis, Marcela, Letzkus, Jaime, Escobar, Paula, Cardemil, Juana Bernardita, Gomez, Henry, Schwartz, Joel, Bonichon-Lamichhane, Natalie, Borstner, Simona, Quispe, Oscar Zambrano, Vestlev, Peter Michael, Danø, Hella, Bews-Hair, Maria, Neades, Glyn, McKirdy, Mike, Fraser, Judith, Murphy, Dermot, Jackisch, Christian, Köcker-Korus, Heike, Stefek, Andrea, Just, Marianne, Bechtner, Christina, Grischke, Eva-Maria, Lorenz, Ralf, Dietz, Wolfgang, Thomalla, Jörg, Graf, Heiko, Busch, Steffi, Tesch, Hans, Krabisch, Petra, Rösel, Siegfried, Josten, Klaus-M, Gröll, Isolde, Mattner, Ute Marie, Garau, Isabel, Climent, Miguel Angel, López, Rafael, Bermejo, Begoña, Amillano, Kepa, Masuda, Norikazu, Toi, Masakazu, Aogi, Kenjiro, Sato, Nobuaki, Tokunaga, Eriko, Fujita, Takashi, Fridrik, Michael, Hackl, Claudia, Wette, Victor, Sevelda, Paul, Thiel, Irene, Tuttlies, Frank, Crown, John, Kennedy, John, McCaffrey, John, Murphy, Conleth, Coate, Linda, Keane, Maccon, O'Connor, Miriam, Duffy, Karen, Zardavas, Dimitrios

“…In animal models of breast cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroduction of letrozole. We therefore…”
Get full text

Abstract PS7-24: Characteristics of HR+/HER2- patients with recurrent disease by HER2 expression from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM) by Álvarez, Isabel, Guerrero, Angel, López-Tarruella, Sara, Martínez, Purificación, Mori, Marta, Falo, Catalina, Antolín, Silvia, Rodríguez, César A, Margeli, Mireia, Garau, Isabel, Tibau, Ariadna, Moreno, Diana, Cruz, Josefina, Echarri, María José, Antón, Antonio, Rodríguez-Lescure, Álvaro, Escudero, María José, Bezares, Susana, Rojo, Federico, Jara, Carlos

“…Abstract Background: The RegistEM study is a non-interventional cohort study that will provide prospective data from >1,800 advanced breast cancer (ABC)…”
Get full text

Abstract PS7-08: Characteristics of HR+/HER2- patients with recurrent disease from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM) by Alvarez, Isabel, Guerrero- Zotano, Angel, López-Tarruella, Sara, Martínez, Purificación, Mori, Marta, Falo, Catalina, Antolin, Silvia, Rodríguez, Cesar A., Margeli, Mireia, Garau, Isabel, Tibau, Ariadna, Moreno, Diana, Cruz, Josefina, Echarri, M. Jose, Lao, Juan, Rodríguez-Lescure, Alvaro, Miralles, Juan Jose, Bezares, Susana, Rojo, Federico, Jara, Carlos

“…Abstract Background: There is limited prospective data for advanced breast cancer (ABC) patients (pts), unresectable locally or metastatic, treated as per…”
Get full text

Abstract OT2-09-01: A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT study) by Pérez-García, José Manuel, Salgado, Alfonso Cortés, Miranda, Elena López, Antón, Antonio, Rovira, Pedro Sánchez, Fernández, Beatriz Castelo, González, Ana López, Garau, Isabel, Martínez, Alejandro, Aparicio, Miguel Corbellas, Barco, Sonia Del, Sampayo, Miguel, Riva, François, Malfettone, Andrea, Llombart-Cussac, Antonio, Cortés, Javier

“…Abstract BACKGROUND: Previous studies have shown prolonged overall survival (OS) in patients with metastatic breast cancer (MBC) treated with eribulin, without…”
Get full text

Abstract OT2-02-06: Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A multi-center, randomized, open-label, phase II trial by Ciruelos, Eva, Villagrasa, Patricia, Oliveira, Mafalda, Pernas, Sonia, Cortes, Javier, Vazquez, Silvia, Martínez, Noelia, Perello, Antonia, Bermejo, Begoña, Martínez, Eduardo, Garau, Isabel, Melé, Mireia, Montaño, Alvaro, Vega, Estela, Cantos, Blanca, Echarri, María Jose, Pascual, Tomás, Canes, Jordi, Céliz, Pamela, González, Xavier, Prat, Aleix

“…Abstract Background: Efficacy Interim results from PATRICIA phase II trial in HER2+/HR+ advanced breast cancer (BC) showed that PAM50 luminal disease was…”
Get full text

Long-term responders to first-line bevacizumab-based therapy in metastatic breast cancer (MBC) patients: Results of the observational study LORENA by Ramos Vazquez, Manuel, Redondo, Andres, Manso, Luis, Gil, Miquel, Garau, Isabel, Perez-Carrion, Ramon, Garcia-Garre, Elisa, Rodriguez, Cesar Augusto, Chacon, Jose Ignacio, Lopez-Vivanco, Guillermo

“…Abstract only e12563 Background: Randomized controlled trials in MBC patients evaluating bevacizumab as first-line treatment showed improvements in tumor…”
Get full text

Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous by Barni, Sandro, Freier, Beata, Garau, Isabel, Mouysset, Jean-Loup, Sediva, Marcela, Zamagni, Claudio, Berdeaux, Gilles, de Almeida Agudo, Cecilia

“…Aim: To assess the burden of disease associated with advanced breast cancer (ABC) treated with oral (VinO) or intravenous vinorelbine (VinIV) from the…”
Get full text

The oxidative stress in breast tumors of postmenopausal women is ERα/ERβ ratio dependent by Sastre-Serra, Jorge, Nadal-Serrano, Mercedes, Pons, Daniel Gabriel, Valle, Adamo, Garau, Isabel, García-Bonafé, Magdalena, Oliver, Jordi, Roca, Pilar

“…Estrogen receptor status is a diagnostic parameter in breast cancer treatment. Estrogen receptor presence is related to a better prognosis because the…”
Get full text

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study by Ortega, Vanesa, Antón, Antonio, Garau, Isabel, Afonso, Noemia, Calvo, Lourdes, Fernández, Yolanda, Martínez-García, María, Blanco, Esperanza, Zamora, Pilar, García, Mirta, Illarramendi, José Juan, Rodríguez Sánchez, César Augusto, Sampayo, Miguel, Aguirre, Elena, Pérez-García, José Manuel, Cortés, Javier, Llombart-Cussac, Antonio

“…Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI)…”
Get full text

Variation in ‘standard care’ for breast cancer across Europe: A EUROCARE-3 high resolution study by Allemani, Claudia, Storm, Hans, Voogd, Adri C, Holli, Kaija, Izarzugaza, IsabeI, Torrella-Ramos, Ana, Bielska-Lasota, Magdalena, Aareleid, Tiiu, Ardanaz, Eva, Colonna, Marc, Crocetti, Emanuele, Danzon, Arlette, Federico, Massimo, Garau, Isabel, Grosclaude, Pascale, Hédelin, Guy, Martinez-Garcia, Carmen, Peignaux, Karin, Plesko, Ivan, Primic-Zakelj, Maja, Rachtan, Jadwiga, Tagliabue, Giovanna, Tumino, Rosario, Traina, Adele, Tryggvadóttir, Laufey, Vercelli, Marina, Sant, Milena

“…Abstract On a population-based sample of 13,500 European breast cancer patients mostly diagnosed in 1996–1998 and archived by 26 cancer registries, we used…”
Get full text

Abstract OT2-2-03: MERIBEL study: Efficacy of eribulin in first line of taxane-resistant patients with HER2 negative metastatic breast cancer by Ortega, Vanessa, Martínez, María, Antón, Antonio, Garau, Isabel, Calvo, Lourdes, Blanco, Esperanza, Fernández, Yolanda, Illarramendi, José Juan, García, Mirta, Llombart, Antonio, Cortés, Javier

“…Abstract Brief background discussion: Eribulin is a nontaxane microtubule dynamics inhibitor. It has shown a significant benefit in overall survival in…”
Get full text

Recent Changes in Breast Cancer Incidence in Spain, 1980–2004 by Pollán, Marina, Pastor-Barriuso, Roberto, Ardanaz, Eva, Argüelles, Marcial, Martos, Carmen, Galcerán, Jaume, Sánchez-Pérez, María-José, Chirlaque, María-Dolores, Larrañaga, Nerea, Martínez-Cobo, Ruth, Tobalina, María-Cres, Vidal, Enrique, Marcos-Gragera, Rafael, Mateos, Antonio, Garau, Isabel, Rojas-Martín, María-Dolores, Jiménez, Rosario, Torrella-Ramos, Ana, Perucha, Josefina, Pérez-de-Rada, Maria-Eugenia, González, Susana, Rabanaque, María-José, Borràs, Joan, Navarro, Carmen, Hernández, Esther, Izquierdo, Ángel, López-Abente, Gonzalo, Martínez, Carmen

“…Background Since the 1980s, Spain experienced two decades of sharply increasing breast cancer incidence. Declines in breast cancer incidence have recently been…”
Get full text

Time to definitive deterioration in patients with metastatic breast cancer subjected to second-line monochemotherapy by Seguí-Palmer, Miguel Angel, Martinez Janez, Noelia, Blanco, Esperanza, Batista, J. Norberto, Munoz, Montserrat, Rodriguez, Cesar Augusto, Fernandez, Isaura, Jerez, Yolanda, Garau, Isabel, Amillano, Kepa, Garcia, Carlos, Perello, Antonia, Santaballa, Ana, Borrega, Pablo, Salvador, Javier, Garcia, Andres, Ruiz, Manuel, Pellin, Lorena, Andres, Raquel

“…Abstract only…”
Get full text

Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study by Manso, Luís, Palomo, Andrés García, Pérez Carrión, Ramón, Cassinello, Javier, Gallegos Sancho, Isabel, Chacón López-Muñiz, Ignacio, Olier, Clara, Fernández-Aramburo, Antonio, Llorca, Cristina, González, Xavier, Llorente, Rosa, Torregrosa, Dolores, Álvarez, Iñaki, Gálve, Elena, Bueno, Coralia, Garau, Isabel, García, María José, González-Santiago, Santiago, Ballesteros, Ana Isabel, Blanco, Esperanza, Galán, Antonio, González, Sonia, Perelló, Antonia, Cortés-Funes, Hernán, Grávalos, Cristina

“…To evaluate factors associated with the selection of first-line bevacizumab plus chemotherapy and clinical response in HER2-negative metastatic breast cancer…”
Get full text

Pleural Mesothelioma Incidence in Europe: Evidence of Some Deceleration in the Increasing Trends by Montanaro, Fabio, Bray, Freddie, Gennaro, Valerio, Merler, Enzo, Tyczynski, Jerzy E., Parkin, Donald Maxwell, ENCR Working Group

“…Objective: To summarize the geographical and temporal variations in incidence of pleural mesothelioma in Europe, using the extensive data available from…”
Get full text

Impact of a registry on survival in familial adenomatous polyposis by Reyes Moreno, José, Ginard Vicens, Daniel, Vanrell, Margalida, Mariñó, Zoe, Garau, Isabel, Llompart, Alfred, Obrador Adrover, Antoni

“…Familial adenomatous polyposis (FAP) is an autosomal dominant inherited disease characterized by hundreds of adenomatous polyps in the large intestine. Almost…”
Get more information